A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

Author:

Yildirim Sedat1ORCID,Dogan Akif1ORCID,Akdag Goncagul1ORCID,Cavdar Eyyup2ORCID,Kinikoglu Oguzcan1ORCID,Oksuz Sila1ORCID,Yildiz Hacer Sahika1ORCID,Kucukoz Uzun Aysun3ORCID,Isik Deniz1ORCID,Surmeli Heves1ORCID,Basoglu Tugba1ORCID,Sever Ozlem Nuray1ORCID,Odabas Hatice1ORCID,Yildirim Mahmut Emre1ORCID,Turan Nedim1ORCID

Affiliation:

1. Department of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul 34865, Turkey

2. Department of Medical Oncology, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdağ 59030, Turkey

3. Department of Nuclear Medicine, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul 34865, Turkey

Abstract

Objective: Immunotherapies are commonly employed for the treatment of non-small-cell lung cancer (NSCLC). However, predictive biomarkers still need to be improved to predict responses to these agents. The lymphocyte–albumin (LA) laboratory index has not been evaluated before in this patient group. The aim of this study was to analyze the relation between the LA index and the survival rate of metastatic NSCLC patients who had immunotherapy after at least one round of chemotherapy. Methods: The research included 227 patients diagnosed with metastatic NSCLC, who were administered nivolumab after at least one round of chemotherapy. The LA index was calculated by multiplying lymphocyte count and albumin concentration. The optimal threshold values for the index were established by the examination of the ROC curve for both overall survival (OS) and progression-free survival (PFS). Oncological data were obtained retrospectively from patient files, and survival analyses were performed. Results: The median follow-up was 7.9 months. Progression was observed in 129 (56.9%) patients. A total of 97 (42.7%) patients died during the follow-up. The cutoff values of the LA index to predict OS and PFS were determined as 52.87 and 57.67, respectively. The low-LA group had significantly lowered OS and PFS compared to the high-LA group. LA was found to be an independent prognostic factor for PFS (hazard ratio 4.47; 95% confidence interval, 2.73–7.34; p < 0.001) and OS (hazard ratio 6.24; 95% confidence interval, 3.46–11.25; p < 0.001) in the multivariate regression analysis. Conclusions: In this study, we observed that the LA index independently predicts OS and PFS in immunotherapy-treated metastatic NSCLC patients. Its ease of application, low cost, and noninvasive nature make it a potential guide for clinicians in predicting treatment responses and survival.

Publisher

MDPI AG

Reference29 articles.

1. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023

2. WHO, and Classification of Tumours Editorial Board (2021). Thoracic Tumours. WHO Classification of Tumours, IARC Publications. [5th ed.].

3. The biology and management of non-small cell lung cancer;Herbst;Nature,2018

4. Five-Year Outcomes from the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer;Borghaei;J. Clin. Oncol.,2021

5. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC;Herbst;J. Thorac. Oncol.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3